Tag: Pharmaceutical Companies
Malady Mongers: How Drug Companies Sell Treatments By Inventing Diseases
From Huffington Post: The pharmaceutical industry’s image has been significantly damaged in recent years as the public discovered the role its aggressive marketing played...
Farewell Mickey Nardo, 1 (not very) Boring Old Man
Mickey studied how the intimacy between leading academic psychiatrists and the pharmaceutical companies had impacted our profession. His blog was a treasure trove of analysis and information. Mickey did some heavy lifting, and for that we are all indebted.
Interview: Researchers Deconstruct Ghostwritten Industry Trial for Antidepressant
Researchers, Jon Jureidini, Jay Amsterdam and Leemon McHenry, have taken a closer look at the data from a randomized control trial of citalopram (Celexa) that was ghostwritten and then used by the manufacturers to support claims of the drug’s efficacy and safety in the treatment of child and adolescent depression. To get the background on this story, we connected with Dr. Leemon McHenry, an investigator in this study and a lecturer in philosophy at California State University, Northridge.
Epidemiologists Decry Major Problems in US Psychiatric Practice
In an exchange published in the Journal of Clinical Epidemiology, researchers take turns highlighting major problems in the way psychiatry is currently practiced in the United States. In response to an article by Vinay Prasad calling for an insistence on randomized control trials in “evidence-based” medicine, Jose de Leon, from the Mental Health Research Center at the University of Kentucky begins the back-and-forth by pointing out that this type of evidence has been detrimental to the field of mental health.
“Holding Big Pharma Accountable: Why Suing the Pharmaceutical Industry Isn’t Working”
Writing for the Huffington Post, Caroline Beaton looks into how drugs continue to make billions in sales even after they lose lawsuits for fraud and misconduct. “The persistence of Big Pharma's fraud despite ubiquitous legal action suggests that our present efforts to hold the industry accountable are ineffective,” Beaton writes. “New polices in motion will make potentially unsafe drugs even easier to bring to market and promote.”